Immix Biopharma is a clinical-stage, US-based, NASDAQ-listed biotechnology company. Its lead asset, NXC-201, is a BCMA-targeting CAR-T cell therapy being developed for relapsed or refractory amyloid light chain amyloidosis (r/r ALA). This is a rare and serious disease in which abnormal plasma cells produce misfolded light chains that can build up in organs, most often the heart, kidneys and liver, leading to progressive organ damage. Immix is now focused on advancing NXC-201 through the US-based NEXICART-2 trial. Patient enrolment was completed in March 2026, with the next update expected in Q326.

There are four key reasons why Immix may be considered a compelling investment opportunity:

1. NXC-201 addresses a rare disease with a clear unmet medical need. Relapsed or refractory ALA remains a difficult-to-treat setting, with no FDA approved therapies specifically available for patients whose disease returns or fails to respond after initial treatment. Existing approaches rely heavily on off-label regimens, which may have limited durability. This creates a meaningful opportunity for a therapy that can deliver deep responses while remaining tolerable for a fragile patient population. NXC-201 is designed to target BCMA, a marker found on disease driving plasma cells. By removing these abnormal plasma cells, the therapy aims to reduce production of the toxic light chains that damage organs. If successful, NXC-201 could become an important new treatment option in an area where patient need remains high, and treatment innovation has been limited.

2. Clinical data to date have been highly encouraging. The latest NEXICART-2 data further strengthen the case for NXC-201. In the first 20 evaluable patients, the complete response rate recently increased to 95%, with 19 out of 20 patients achieving a complete response. This follows the conversion of all four patients who were previously measurable residual disease negative, supporting the potential for responses to deepen over time. Importantly, all complete responses were reached within one year of dosing, and no relapses have been observed to date among patients who achieved complete response. Management has also disclosed that all subsequently enrolled patients with available measurable residual disease data had achieved measurable residual disease negativity at one month. While longer follow-up remains important, these results suggest NXC-201 may deliver rapid, deep and potentially durable responses.

3. The safety profile could offer a meaningful differentiation point. CAR-T therapies can be highly effective, but their use has often been constrained by safety, monitoring and hospital resource requirements. This is especially important in ALA, where the patient population is relatively fragile. NXC-201 has so far shown a favourable safety profile. In the 20-patient dataset, no cases of neurotoxicity were reported, and cytokine release syndrome, an inflammatory reaction seen with CAR-T therapies, was low grade and considered manageable. There was also no unexpected or lasting cardiac toxicity, despite cardiac involvement in many patients at enrolment. This safety profile is central to the investment case. If maintained in the final dataset, it may support the positioning of NXC-201 as a potential outpatient CAR-T therapy. That could reduce the need for prolonged hospitalisation, ease pressure on specialist treatment centres and improve patient access.

4. Immix is well funded through key upcoming milestones. Immix has strengthened its financial position with the closing of a $150m underwritten public offering of common stock and pre-funded warrants. Net proceeds are expected to be c $141m, supporting ongoing clinical development, working capital and general corporate purposes. Management estimates that the company’s cash resources should now provide a runway to mid-2028. This is important given the upcoming clinical and regulatory milestones for NXC-201. NEXICART-2 has completed patient enrolment, with 45 patients enrolled, and the next update remains on track for September 2026. One-year follow-up data are expected by end-March 2027 and are expected to support the path towards BLA submission and commercial launch. The extended runway reduces near-term funding pressure and gives Immix greater flexibility as it advances NXC-201 through a potentially pivotal stage.

In summary, Immix presents a focused investment case centred on NXC-201, a promising CAR-T therapy for a rare disease with significant unmet need. With encouraging clinical data, a differentiated safety profile, near-term regulatory catalysts and a strengthened financial position, Immix is entering an important period of potential value creation.

Published 6 July 2026